Abstract:Introduction To date, no specific therapies have been approved for immunoglobulin A nephropathy (IgAN) treatment. Telitacicept is a fusion protein composed of a transmembrane activator, transmembrane activator and CAML interactor (TACI), and fragment crystallizable (Fc) portion of immunoglobulin G (IgG), which neutralizes the B lymphocyte stimulator and a proliferation-inducing ligand. Methods This phase 2 randomized placebo-controlled trial aimed to evaluate the efficacy and safety of telitacicept in patients with IgAN. Participants with an estimated glomerular filtration rate (eGFR) >35 mL/min/1.73 m 2 and proteinuria ≥ 0.75 g/day despite optimal supportive therapy were randomized 1:1:1 to receive subcutaneous telitacicept 160 mg, telitacicept 240 mg, or placebo weekly for 24 weeks. The primary endpoint was the change in 24-hour proteinuria at week 24 from baseline. Results Forty-four participants were randomized into placebo (14), telitacicept 160 mg (16), and telitacicept 240 mg (14) groups. Continuous reductions in serum IgA, IgG, and IgM levels were observed in the telitacicept group. Telitacicept 240 mg therapy reduced mean proteinuria by 49% from baseline (change in proteinuria vs. placebo, 0.88; 95% confidence interval, -1.57 to -0.20; p=0.013), while telitacicept 160 mg reduced it by 25% (-0.29; 95% CI, -0.95 to 0.37; p=0.389). The eGFR remained stable over time. Adverse events (AEs) were similar in all groups. Treatment-emergent AEs were mild or moderate, and no severe AEs were reported. Conclusion Telitacicept treatment led to a clinically meaningful reduction in proteinuria in patients with IgAN in the present phase 2 clinical trial. This effect is indicative of a reduced risk for future kidney disease progression.

Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria